Presentation R&D Day
WHAT LIES AHEAD FOR IMMUNO-ONCOLOGY
Many tumors are not adequately responsive to checkpoint inhibitors and other IO approaches. Can we use radiation and nanoparticles to stimulate an immune response against a tumor? Watch video #5 to hear Dr. James Welsh to learn what advances are being developed in immunooncology, radiotherapy and nanomedicine.
STUDY 1100: CAN WE TURN COLD TUMORS HOT?
Once in a while, we as researchers must try something new and has the potential to revolutionize the treatment landscape. Once in a while, we as researchers must try something new and has the potential to revolutionize the treatment landscape. The 1100 trial selects patients who have failed radiation and are not likely to be cured.Preclinical and clinical data suggest that NBTXR3 has the potential to turn CPI non-responders into responders, and that these nanoparticles help induce immunogenesis, turning “cold” tumors into “hot” ones, allowing the immune system to recognize the tumor and get equipped against it. Dr. Tanguy Seiwert maps out Nanobiotix’s Phase I/II 1100 trial studying the potential immunogenic effect of NBTXR3 in head & neck cancer and non-small cell lung cancer patients.
BIRTH OF NBTXR3
“20 years ago, I asked myself: Can we influence a cell by impacting its physics at the subcellular level?” Laurent Levy examines the importance of asking different questions, and how this leads to disruptive healthcare. This video presents how NBTXR3’s technology came into being, and the developments of NBTXR3 in clinical trials.
Multidisciplinary Head & Neck Symposium
Locally advanced head and neck cancer patients that are ineligible for cisplatin face a variety of unmet needs, and disruptive innovation in radiation therapy could provide benefits for this population. Leading medical experts will discuss the company and its novel radioenhancer NBTXR3, an aqueous suspension of crystalline hafnium oxide that, after intramural injection prior to a patient’s first radiation therapy session, increases the energy deposit from ionizing radiation within the cell without increasing the dose in surrounding healthy tissues.
NBTXR3 Intratumoral Injection
“Intratumoral injection of NBTXR3 is feasible and safe and NBTXR3 remains localized within the tumor throughout RT treatment.”
Head & Neck cancer phase I trial
“Radiotherapy is the only option to treat this fragile H&N Cancer population and benefits are limited.”
“Changing the treatment paradigm for millions of patients by bringing nanophysics to the heart of the cell.”
Study 1100 Phase I Results Webinar
STUDY 1100 PHASE I RESULTS WEBINAR
A webinar was held on Friday, 13 November 2020 presenting a deep-dive on the positive first results of NBTXR3 in Immuno-Oncology. Moderated by Dr. Jeff Bockman, EVP, Oncology Practice Head, Cello Health, speakers include Laurent Levy, CEO, Nanobiotix, Dr. Colette Shen, Assistant Professor, Radiation Oncology and Dr. Jared Weiss, Assistant Professor of Medicine, both from UNC Lineberger Comprehensive Cancer Center and Dr. James Welsh, Radiation Oncologist & Professor, The University of Texas, MD Anderson Cancer Center.
The French society of Radiation Oncology (SFRO) was created in 1990 and serves the purpose of promoting the teaching of radiation oncology in France.
Nanobiotix presented during the French Society of Radiation Oncology annual congress on Developping the potential of radiation therapy with NBTXR3 in head and neck cancers.
Presentation R&D Day
The Nanobiotix first R&D day was held in New York on 27 September 2018. The aim of this event was to discuss the latest development in the fields of radiation oncology, immunotherapy and nanomedicine along with the Nanobiotix leadership team and leading medical experts. Please click below to see our R&D Day videos.
This TEDx talk with Laurent Levy was filmed on 28 November 2013 at “Gaîté Lyrique” in Paris. Discover the video of Laurent Levy, CEO of Nanobiotix on the importance of nanomedicine for the treatment of cancers.
17 years ago, Laurent LEVY, Pioneer of Nanomedicine, researcher and entrepreneur, was one of the first entrepreneurs to believe and work on the development of nanomedicines for cancer treatment. Laurent Levy holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie) in Paris and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives). In 2003, he founded NANOBIOTIX, one of the most promising biotechs in France.